A press release reports that LivaNova is to discontinue its Caisson transcatheter mitral valve replacement programme and will undertake a restructuring of its heart valve business to improve profitability and ensure business continuity. It adds that LivaNova’s heart valve business line represented nearly $130 million in revenue for full-year 2018 and has experienced a [...]